Potential of Diabetes Medications in Treating Alcohol Use Disorder

Recent research indicates that medications traditionally used for managing diabetes, specifically GLP-1 and GIP receptor agonists, may hold promise in addressing alcohol use disorder (AUD). A large-scale genetic analysis conducted by scientists at the National Institute on Alcohol Abuse and Alcoholism explored the influence of these hormones on alcohol consumption behaviors and liver health. By applying drug-target Mendelian randomization — a method that leverages genetic data to predict drug effects — researchers found that naturally occurring variations affecting GLP1R and GIPR genes were associated with reduced binge drinking and lower risk of heavy alcohol use. Notably, these genetic proxies for lowered BMI and appetite regulation correlated with decreased alcohol intake and preferences for healthier foods, such as vegetarian options, as well as improved liver function indicators like reduced NAFLD and ALT levels.

The findings suggest that drugs targeting GLP-1 and GIP receptors, already used for obesity and diabetes, could potentially be repurposed to treat AUD. This approach could also influence appetite and cravings, offering a dual benefit in managing both alcohol consumption and metabolic health. While the study did not directly test the effects of these medications on humans with AUD, it provides a foundational understanding that could guide future clinical trials. The potential to reduce hazardous drinking and improve liver health emphasizes the importance of exploring these hormonal pathways further.

Overall, this research highlights the innovative use of genetic data to identify new therapeutic avenues for alcohol use disorder, opening doors to more effective and targeted treatments in the future.

Source: https://medicalxpress.com/news/2025-10-diabetes-drugs-treatment-alcohol-disorder.html